KORU Medical Systems Inc

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

KORU Medical Systems reports robust Q4 growth and eyes international expansion

KORU Medical Systems demonstrated strong financial performance in Q4 2022, with revenue growth and cash position exceeding expectations.
The company's strategic focus on novel therapies and international expansion presents growth opportunities, though margin improvement and market challenges remain.
With a clear Vision 26 strategy and positive revenue guidance for 2023, KORU is poised for continued growth and market leadership.

KORU Medical Systems excels in Q1 2023, poised for strategic growth

KORU Medical Systems delivered a robust performance in Q1 2023, showcasing growth across key business segments and strategic initiatives.
The company's focus on revenue targets, margin improvement, and operational efficiency positions it well for future success.
While challenges like managing cash burn and market dynamics exist, KORU's strengths in product leadership and financial management offer resilience.
Strategic opportunities in market expansion, innovation, and customer value creation provide a positive outlook for the company's growth trajectory.

KORU Medical Systems reports Q2 growth, projects improved margins

KORU Medical Systems demonstrated overall growth in Q2 2023, driven by strong performance in core businesses and improving gross margins. While facing challenges in Novel Therapies and a net cash operating loss, the company remains optimistic about future revenue growth and strategic initiatives.

KORU Medical Systems Inc reports Q3 revenue decline, focuses on margin expansion and Novel Therapies collaborations

KORU Medical Systems Inc faces revenue challenges but focuses on margin expansion, expense control, and strategic investments. The company aims for cash flow breakeven by Q4 2024, emphasizing Novel Therapies business and market growth assumptions.

KORU Medical Systems reports solid Q4 growth and outlines expansion plans for 2024

KORU Medical Systems' Q4 2023 performance reflects steady growth and strategic advancements in product development and market expansion. While facing challenges in production efficiency and European certification, the company is well-positioned to capitalize on opportunities in prefilled syringes and novel therapies for future growth.

KORU Medical Systems achieves record revenue and eyes global expansion

KORU Medical Systems delivered strong Q1 2024 results with record revenue and gross margin, alongside reduced cash burn.
The company reaffirmed guidance, secured new collaborations, and expanded internationally, while facing regulatory approval challenges.
Opportunities lie in FDA approvals, cash flow targets, and sustained U.S. core business growth through innovations and partnerships.

KORU Medical Systems excels in Q3, eyes growth opportunities

KORU Medical Systems delivered robust financial performance in Q3 2024, with raised revenue guidance and expectations of cash flow positivity in 2025.
The company's strategic focus on new product development and market expansion positions it well for sustained growth and profitability.
While facing challenges in maintaining growth momentum and operational efficiency, KORU's strong performance and outlook signal a promising future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KORU Medical Systems, Inc. (KRMD) Q3 2024 Earnings Call Transcript

KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2024, and raised full year 2024 revenue, gross margin, and year-end cash guidance. Recent Highlights Third quarter 2024 net revenues of $8.

KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in two upcoming Investor Conferences. KORU Medical's management team is participating at the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, Novemb.

KORU Medical Systems to Participate in Upcoming Investor Conferences

KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials.

Impressive Turnaround At KORU Medical

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large-volume subcutaneous infusion solutions, this week presented data demonstrating nursing preference for the use of the KORU FreedomEdge® Infusion System to administer subcutaneous oncology infusions in the clinic setting. The results of the case study wer.

KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2024 financial results on Wednesday, November 13, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss th.

KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in investor meetings at the 8th Annual Lake Street Best Ideas Growth Conference in New York on Thursday, September 12, 2024. About KORU Medical Systems KORU Med.

KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference

KORU Medical Systems, Inc (KRMD) Q2 2024 Earnings Call Transcript

KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.

KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2024 and raised full year 2024 revenue and gross margin guidance. Financial Highlights Second quarter 2024 net revenues of $8.4 million, a 22%.

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024. KORU Medical's management is scheduled to present at the Canaccord Genuity 44th Annual Gro.

KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the promotion of Christopher Pazdan, to Chief Operating Officer, effective July 18, 2024. Mr. Pazdan has been with the organization since 2021, and last served as the Company's Senior Vice Pres.

KORU Medical Systems, Inc Announces Leadership Changes to Support Growth Agenda

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 7, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the.

KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024

KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.

KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that its state-of-the-art FreedomEdge® System has received regulatory clearance in Japan for the delivery of multiple drugs, including CSL Behring's Hizentra subcutaneous immunoglobulin (SCIg), Tak.

KORU Medical Systems Receives Regulatory Clearance for FreedomEdge® Infusion System in Japan

MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. “We want to ensure that medications are safe and easy to use for.

Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical's Freedom Infusion System (the “Freedom System”) for an FDA and EMA approved subcutaneous onco.

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease. This significant milestone marks the progression of this.

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Linda Tharby - President & Chief Executive Officer Tom Adams - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum William Wood - B. Riley Securities Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Operator Greetings and welcome to the KORU Medical Systems' First Quarter 2024 Financial Results Conference Call and Webcast.

KORU Medical Systems, Inc. (KRMD) Q1 2024 Earnings Call Transcript

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenue.

KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the fina.

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI). The Company's appeal of an assessment report from BSI regarding a recommendati.

News for KORU Medical Systems Inc Stock (KRMD)